Header Logo

Connection

CHARLES WYKOFF to Tomography, Optical Coherence

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Tomography, Optical Coherence.
CHARLES WYKOFF
Connection Strength
8.465
Tomography, Optical Coherence
  1. Morphologic Stages of Full-Thickness Macular Hole on Spectral-Domain OCT. Ophthalmol Retina. 2025 Apr; 9(4):305-313.
    View in: PubMed
    Score: 0.660
  2. CLINICALLY RELEVANT POSTERIOR VITREOUS DETACHMENT STAGING USING CIRCUMPAPILLARY AND MACULAR VOLUME OPTICAL COHERENCE TOMOGRAPHY. Retina. 2024 08 01; 44(8):1441-1448.
    View in: PubMed
    Score: 0.649
  3. Clinically Labeled Contrastive Learning for OCT Biomarker Classification. IEEE J Biomed Health Inform. 2023 09; 27(9):4397-4408.
    View in: PubMed
    Score: 0.610
  4. Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2018 09 01; 49(9):692-697.
    View in: PubMed
    Score: 0.431
  5. THE ASSOCIATION OF EPIRETINAL MEMBRANE WITH MACULAR HOLE FORMATION AFTER RHEGMATOGENOUS RETINAL DETACHMENT REPAIR. Retina. 2017 Jun; 37(6):1073-1078.
    View in: PubMed
    Score: 0.395
  6. Intraoperative OCT of a full-thickness macular hole before and after internal limiting membrane peeling. Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb; 41(1):7-11.
    View in: PubMed
    Score: 0.236
  7. Risk factors for development of hyper-reflective foci overlying drusen in eyes with intermediate age-related macular degeneration. Br J Ophthalmol. 2024 Aug 22; 108(9):1234-1239.
    View in: PubMed
    Score: 0.163
  8. Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy. Can J Ophthalmol. 2025 Apr; 60(2):91-99.
    View in: PubMed
    Score: 0.163
  9. MANAGEMENT OF LARGE FULL-THICKNESS MACULAR HOLES: Long-Term Outcomes of Internal Limiting Membrane Flaps and Internal Limiting Membrane Peels. Retina. 2024 07 01; 44(7):1165-1170.
    View in: PubMed
    Score: 0.161
  10. Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration: A Cross Sectional Study. Ophthalmol Retina. 2024 Sep; 8(9):854-862.
    View in: PubMed
    Score: 0.159
  11. Predictive Factors Influencing the Evolution of Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration Eyes. Ophthalmol Retina. 2024 Sep; 8(9):863-871.
    View in: PubMed
    Score: 0.159
  12. Topographic analysis of local OCT biomarkers which predict progression to atrophy in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024 Jul; 262(7):2083-2091.
    View in: PubMed
    Score: 0.157
  13. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun; 131(6):708-723.
    View in: PubMed
    Score: 0.156
  14. Diagnosis and Management of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Delphi Consensus Exercise. Ophthalmic Surg Lasers Imaging Retina. 2023 10; 54(10):589-598.
    View in: PubMed
    Score: 0.153
  15. OCT Risk Factors for Development of Atrophy in Eyes with Intermediate Age-Related Macular Degeneration. Ophthalmol Retina. 2023 03; 7(3):253-260.
    View in: PubMed
    Score: 0.143
  16. Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2022 07; 6(7):557-566.
    View in: PubMed
    Score: 0.137
  17. Weakly-Supervised Vessel Detection in Ultra-Widefield Fundus Photography via Iterative Multi-Modal Registration and Learning. IEEE Trans Med Imaging. 2021 10; 40(10):2748-2758.
    View in: PubMed
    Score: 0.133
  18. Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 03; 235:131-142.
    View in: PubMed
    Score: 0.133
  19. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021 09; 128(9):1325-1336.
    View in: PubMed
    Score: 0.128
  20. Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study. Am J Ophthalmol. 2021 02; 222:328-339.
    View in: PubMed
    Score: 0.124
  21. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy. Ophthalmol Retina. 2021 05; 5(5):409-419.
    View in: PubMed
    Score: 0.124
  22. Home Monitoring of Age-Related Macular Degeneration: Utility of the ForeseeHome Device for Detection of Neovascularization. Ophthalmol Retina. 2021 04; 5(4):348-356.
    View in: PubMed
    Score: 0.123
  23. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 08 01; 138(8):851-857.
    View in: PubMed
    Score: 0.123
  24. Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes. Ophthalmic Surg Lasers Imaging Retina. 2019 09 01; 50(9):e250-e256.
    View in: PubMed
    Score: 0.115
  25. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. Ophthalmol Retina. 2019 12; 3(12):1076-1086.
    View in: PubMed
    Score: 0.115
  26. Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. Am J Ophthalmol. 2019 10; 206:74-81.
    View in: PubMed
    Score: 0.112
  27. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol. 2019 06; 202:91-99.
    View in: PubMed
    Score: 0.111
  28. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019 Aug; 97(5):460-472.
    View in: PubMed
    Score: 0.111
  29. Fovea-sparing rhegmatogenous retinal detachments: impact of clinical factors including time to surgery on visual and anatomic outcomes. Graefes Arch Clin Exp Ophthalmol. 2019 May; 257(5):883-889.
    View in: PubMed
    Score: 0.110
  30. Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial. Ophthalmic Surg Lasers Imaging Retina. 2018 04 01; 49(4):258-264.
    View in: PubMed
    Score: 0.105
  31. Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. Graefes Arch Clin Exp Ophthalmol. 2018 Mar; 256(3):511-518.
    View in: PubMed
    Score: 0.103
  32. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. Am J Ophthalmol. 2017 Aug; 180:8-17.
    View in: PubMed
    Score: 0.099
  33. Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis: Clinical Characteristics of 36 Eyes. Ophthalmology. 2017 05; 124(5):583-595.
    View in: PubMed
    Score: 0.096
  34. Diagnostic and Therapeutic Challenges. Retina. 2016 Nov; 36(11):2239-2245.
    View in: PubMed
    Score: 0.095
  35. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. Am J Ophthalmol. 2017 Jan; 173:56-63.
    View in: PubMed
    Score: 0.094
  36. GRANULAR HYPERREFLECTIVE SPECKS BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS SIGNS OF WEST NILE VIRUS INFECTION: THE STARDUST SIGN. Retin Cases Brief Rep. 2016; 10(4):349-53.
    View in: PubMed
    Score: 0.090
  37. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmology. 2015 Dec; 122(12):2514-22.
    View in: PubMed
    Score: 0.088
  38. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014 Jul; 98(7):951-5.
    View in: PubMed
    Score: 0.079
  39. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Retina. 2014 Jan; 34(1):48-54.
    View in: PubMed
    Score: 0.078
  40. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology. 2013 Sep; 120(9):1945-6.e1.
    View in: PubMed
    Score: 0.076
  41. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr; 44(2):121-6.
    View in: PubMed
    Score: 0.074
  42. Progressive inner retinal neurodegeneration in non-proliferative macular telangiectasia type 2. Br J Ophthalmol. 2025 Feb 24; 109(3):401-407.
    View in: PubMed
    Score: 0.042
  43. Accurate prediction of disease-risk factors from volumetric medical scans by a deep vision model pre-trained with 2D scans. Nat Biomed Eng. 2025 Apr; 9(4):507-520.
    View in: PubMed
    Score: 0.041
  44. MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2025 Feb; 132(2):131-140.
    View in: PubMed
    Score: 0.041
  45. Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration. Can J Ophthalmol. 2025 Feb; 60(1):e92-e99.
    View in: PubMed
    Score: 0.040
  46. Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial. Ocul Immunol Inflamm. 2024 Oct; 32(8):1556-1563.
    View in: PubMed
    Score: 0.039
  47. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial. Ophthalmol Retina. 2024 Feb; 8(2):116-125.
    View in: PubMed
    Score: 0.038
  48. Surgical Management of Full-Thickness Macular Holes in Macular Telangiectasia Type 2: A Global Multicenter Study. Ophthalmology. 2024 Jan; 131(1):66-77.
    View in: PubMed
    Score: 0.038
  49. USE OF OPTICAL COHERENCE TOMOGRAPHY IN DETECTING RETINAL TEARS IN ACUTE, SYMPTOMATIC POSTERIOR VITREOUS DETACHMENT. Retina. 2023 05 01; 43(5):802-807.
    View in: PubMed
    Score: 0.037
  50. Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study. Eye (Lond). 2023 Jun; 37(9):1928-1935.
    View in: PubMed
    Score: 0.036
  51. Optical Coherence Tomography Biomarkers for Conversion to Exudative Neovascular Age-related Macular Degeneration. Am J Ophthalmol. 2023 03; 247:137-144.
    View in: PubMed
    Score: 0.036
  52. RETINAL VASCULAR BED AREA IN EYES WITH RETINAL VEIN OCCLUSION ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY: WAVE Study. Retina. 2022 10 01; 42(10):1883-1888.
    View in: PubMed
    Score: 0.036
  53. Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study. Eye (Lond). 2023 03; 37(4):678-683.
    View in: PubMed
    Score: 0.034
  54. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies. Retina. 2022 03 01; 42(3):511-518.
    View in: PubMed
    Score: 0.034
  55. Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data. Am J Ophthalmol. 2022 04; 236:12-19.
    View in: PubMed
    Score: 0.033
  56. Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. Br J Ophthalmol. 2023 03; 107(3):399-405.
    View in: PubMed
    Score: 0.033
  57. RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2021 Aug 01; 41(8):1579-1586.
    View in: PubMed
    Score: 0.033
  58. Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021 May 01; 139(5):542-547.
    View in: PubMed
    Score: 0.032
  59. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021 07; 128(7):1027-1038.
    View in: PubMed
    Score: 0.031
  60. RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY. Retina. 2020 Nov; 40(11):2175-2183.
    View in: PubMed
    Score: 0.031
  61. Automated vessel density detection in fluorescein angiography images correlates with vision in proliferative diabetic retinopathy. PLoS One. 2020; 15(9):e0238958.
    View in: PubMed
    Score: 0.031
  62. Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study. Br J Ophthalmol. 2021 08; 105(8):1111-1115.
    View in: PubMed
    Score: 0.031
  63. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. Ophthalmol Retina. 2021 01; 5(1):60-70.
    View in: PubMed
    Score: 0.031
  64. SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study. Retina. 2020 Jun; 40(6):1029-1037.
    View in: PubMed
    Score: 0.030
  65. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Br J Ophthalmol. 2021 02; 105(2):253-257.
    View in: PubMed
    Score: 0.030
  66. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020 10; 127(10):1331-1344.
    View in: PubMed
    Score: 0.030
  67. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 04 01; 138(4):341-349.
    View in: PubMed
    Score: 0.030
  68. THE TEXAS TACO TECHNIQUE FOR INTERNAL LIMITING MEMBRANE FLAP IN LARGE FULL-THICKNESS MACULAR HOLES: A Short-Term Pilot Study. Retina. 2020 Mar; 40(3):552-556.
    View in: PubMed
    Score: 0.030
  69. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. Eye (Lond). 2020 03; 34(3):480-490.
    View in: PubMed
    Score: 0.029
  70. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 02; 127(2):186-195.
    View in: PubMed
    Score: 0.029
  71. Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1. Am J Ophthalmol. 2019 10; 206:154-160.
    View in: PubMed
    Score: 0.028
  72. Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration. Invest Ophthalmol Vis Sci. 2019 05 01; 60(6):2134-2139.
    View in: PubMed
    Score: 0.028
  73. Ultra-Wide-Field Fluorescein Angiography-Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 2018 07 02; 59(8):3278-3285.
    View in: PubMed
    Score: 0.027
  74. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. Am J Ophthalmol. 2018 08; 192:84-90.
    View in: PubMed
    Score: 0.026
  75. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2018 08; 125(8):1304-1306.
    View in: PubMed
    Score: 0.026
  76. Five-Year Outcomes of Surgically Treated Symptomatic Epiretinal Membranes With and Without Internal Limiting Membrane Peeling. Ophthalmic Surg Lasers Imaging Retina. 2018 05 01; 49(5):296-302.
    View in: PubMed
    Score: 0.026
  77. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Ophthalmology. 2018 07; 125(7):1054-1063.
    View in: PubMed
    Score: 0.026
  78. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Ophthalmology. 2018 05; 125(5):683-690.
    View in: PubMed
    Score: 0.026
  79. Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. Am J Ophthalmol. 2017 Aug; 180:110-116.
    View in: PubMed
    Score: 0.025
  80. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2017 02; 124(2):215-223.
    View in: PubMed
    Score: 0.024
  81. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. Can J Ophthalmol. 2015 Oct; 50(5):373-7.
    View in: PubMed
    Score: 0.022
  82. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina. 2014 Sep; 34(9):1728-35.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.